NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









GeneMind Biosciences Co., Ltd.

GeneMind Biosciences Co., Ltd.

Private
ShenzhenHealthcare & Life Scienceshttps://www.genemind.com/

Last Round

Series C

Extension

May 28, 2025

Est. Valuation

$573.5M

Total Funding Raised

$218M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

GeneMind Biosciences Co., Ltd. is a biotechnology company that develops and manufactures DNA sequencing systems and molecular diagnostic technology platforms for clinical and research applications.

Sector

Healthcare & Life Sciences

Verticals

Biotech Equipment, Medical Devices, Precision Medicine, Biotechnology

Business Model

B2B

Customer Profile

Usage-Based SaaS, Hardware Sales, Services & Consulting

AI Layer

Application

Keywords

DNA sequencingnext-generation sequencingNGSmolecular diagnosticssequencing-by-synthesisSBSgenomic dataprecision medicinesequencing instrumentsgenomics hardwarerazor-and-bladesample preparationbasecallingbiotech equipmentgenomics lab

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GeneMind Biosciences Co., Ltd. Comparables

Compare GeneMind Biosciences Co., Ltd. with similar companies based on industry and business-model similarity.

GeneMind Biosciences Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cygnus Biosciences (Beijing) Co., Ltd.
84%
Axbio
81%
Element Biosciences
81%

GeneMind Biosciences Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionMay 28, 2025
Series CAug 2, 2023
Series B ExtensionSep 15, 2021
StrategicJun 21, 2021
Series BSep 1, 2020
Series A Extension
Jan 1, 2020

Key People

Founding team and executive leadership

Lei Sun

CTO

Executive Team

Zhiliang Zhou

Chief Operating Officer, VP R&D

Executive Team

GeneMind Biosciences Co., Ltd. Investors

Notable investors and investment history

GeneMind Biosciences Co., Ltd. investors
InvestorRounds
Sincere CapitalSeries B
Shenzhen HTI GroupSeries C
Cowin CapitalSeries B Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 23, 2026

    Grew 19% QoQ, from 53 to 63 employees.

  • May 7, 2026

    Grew 24% QoQ, from 50 to 62 employees.

GeneMind Biosciences Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

GeneMind Biosciences Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about GeneMind Biosciences Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersShenzhen
Employee Range65
Year Founded2012
Last FundingMay 28, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.